NASDAQ : GDTC
CytoMed Therapeutics Limited — Key statistics
Healthcare · Biotechnology · Singapore
Last price 0.9006 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 10.75M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 10.86M |
| Enterprise Value | 10.08M |
Dates
| Measure | Value |
|---|
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 11.93M |
| Shares Outstanding | 11.93M |
| Shares Change (YoY) | +2.40% |
| Shares Change (QoQ) | +1.07% |
| Owned by Insiders (%) | 21.51% |
| Owned by Institutions (%) | 0.14% |
| Float | 3.52M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 17.81 |
| Forward PS | n/a |
| PB Ratio | 2.83 |
| P/TBV Ratio | 2.89 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 16.54 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.64 |
| Quick Ratio | 1.51 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -192.87 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -56.17% |
| Return on Assets (ROA) | -32.52% |
| Return on Invested Capital (ROIC) | -36.85% |
| Return on Capital Employed (ROCE) | -69.06% |
| Weighted Average Cost of Capital (WACC) | 4.61% |
| Revenue Per Employee | $14,517 |
| Profits Per Employee | -$64,527 |
| Employee Count | 42 |
| Asset Turnover | 0.10 |
| Inventory Turnover | 0.12 |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.07 |
| 52-Week Price Change | -58.65% |
| 50-Day Moving Average | 0.90 |
| 200-Day Moving Average | 0.98 |
| Relative Strength Index (RSI) | 50.76 |
| Average Volume (20 Days) | 16,345 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 19,350 |
| Short Previous Month | 17,102 |
| Short % of Shares Out | 0.16% |
| Short % of Float | 0.55% |
| Short Ratio (days to cover) | 0.93 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 609,727 |
| Gross Profit | 523,720 |
| Operating Income | -3.09M |
| Pretax Income | -2.74M |
| Net Income | -2.71M |
| EBITDA | -2.75M |
| EBIT | -3.09M |
| Loss Per Share | -$0.23 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 1.13M |
| Total Debt | 350,929 |
| Net Cash | 776,322 |
| Net Cash Per Share | $0.07 |
| Equity (Book Value) | 4.17M |
| Book Value Per Share | 0.32 |
| Working Capital | 1.55M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -2.93M |
| Capital Expenditures | -372,545 |
| Depreciation & Amortization | 344,730 |
| Net Borrowing | 734,569 |
| Free Cash Flow | -3.30M |
| FCF Per Share | -$0.28 |
Margins
| Measure | Value |
|---|
| Gross Margin | 85.89% |
| Operating Margin | -506.84% |
| Pretax Margin | -449.24% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -2.40% |
| Shareholder Yield | -2.40% |
| Earnings Yield | -25.21% |
| FCF Yield | -30.39% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 2.81 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |